TALZENNA caps 0.5 mg bte 30 pce

7680671410099 CH-67141 L01XK04 07.16.1.

Reimbursement limitations:

TALZENNA

Uniquement sur prescription par un médecin spécialiste en gynécologie ou en oncologie et après accord …

TALZENNA caps 0.5 mg bte 30 pce
TALZENNA caps 0.5 mg bte 30 pce
TALZENNA caps 0.5 mg bte 30 pce
1 / 3
google

Details

Product number
6714105
CPT
-
Packaging group
30
Unit
Kapsel(n)
Composition
talazoparibum 0.5 mg ut talazoparibi tosilas, cellulosum microcristallinum silicificatum, Kapselhülle: hypromellosum, E 171, E 172 (rubrum), Drucktinte: lacca, propylenglycolum, ammonii hydroxidum, E 172 (nigrum), kalii hydroxidum, pro capsula.

Articles (1)

Talzenna 0.5 mg, Hartkapseln
Kapseln
30
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
15/10/2025
Professional SmPC
Français
15/10/2025
Professional SmPC
Italien
15/10/2025
Patient information leaflet
Allemand
29/08/2024
Patient information leaflet
Français
29/08/2024
Patient information leaflet
Italien
29/08/2024

Detailed composition

Substance Quantity Type Category
(N/A)
0.5 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance FTODK
(N/A)
- Substance HNIDK

Reimbursement information

Public price
CHF 2895.15
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/11/2024

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
67141
Drug name
Talzenna, Hartkapseln
Galenic form
KAPS
ATC Code
L01XK04
Authorization status
Z
Dispensation category
A
First authorization
12/12/2019
Authorization expiration date
31/12/9999
IT number
07.16.1.
Domain
Human medicine
Field of application
Lokal fortgeschrittenes oder metastasiertes HER2-negatives Mammakarzinom mit einer Keimbahn-BRCA-Mutation, nach einer Anthracyclin- und/oder einer Taxan-Behandlung entweder in neoadjuvanter, adjuvanter oder lokal fortgeschrittener/metastasierter Situation; in Kombination mit Enzalutamid: metastasiertes, kastrationsresistentes Prostatakarzinom mit Mutationen in homologen Rekombinationsreparaturgenen ([HRR] Gen-mutiert), wenn eine Chemotherapie klinisch nicht indiziert ist.

Packaging details

Description (FR)
TALZENNA caps 0.5 mg bte 30 pce
Description (DE)
TALZENNA Kaps 0.5 mg Ds 30 Stk
Market launch
12/07/2024
Narcotic (BTM)
No

Other packaging sizes

TALZENNA caps 0.25 mg bte 30 pce
30 KAP
GTIN: 7680671410020
View
TALZENNA caps 1 mg bte 30 pce
30 KAP
GTIN: 7680671410068
View
TALZENNA caps 0.1 mg bte 30 pce
30 KAP
GTIN: 7680671410075
View
TALZENNA caps 0.35 mg bte 30 pce
30 KAP
GTIN: 7680671410082
View